|
For the quarter ended Sep 18, consolidated net sales stood at Rs 683.47 crore up by 7% YoY. OPM stood at 18.2% down by 150 bps thus resulting in fall in OP by 6% to Rs 124.71 crore. Other income stood at Rs 5.70 crore up by 18%. Interest cost and depreciation cost stood at Rs 15.98 crore and Rs 44.99 crore respectively. PBT stood at Rs 69.44 crore down by 14% YoY. After providing total tax of Rs 20.48 crore and loss of share of associates of Rs 4.41 crore, consolidated PAT for Sep 18 quarter stood at Rs 53.37 crore up by 2% YoY.
For the quarter, sales from the Amesa geography stood at Rs 233.66 crore, down by 1% YoY and accounted for 33% of the total sales. PBIT from the same stood at Rs 26.78 crore down by 27% YoY and accounted for 31% of total PBIT.
For the quarter, sales from the EAP geography stood at Rs 184.7 crore, up by 17% YoY and accounted for 26% of total sales and PBIT from the same stood at Rs 36.05 crore up by 22% YoY with PBIT margin at 19.5% as compared to 18.7% for Sep 17 quarter.
For the quarter, sales from the America geography stood at Rs 143.50 crore and PBIT from the same stood at Rs 19.20 crore down by 9% YoY. PBIT margin stood at 13.4% as compared to 16.4% for Sep 17 quarter.
For the quarter, sales from the EU geography stood at Rs 147.88 crore up by 12% YoY and PBIT stood at Rs 3.78 crore down by 41% YoY with PBIT margin at 2.6% as compared to 4.8% for Sep 17 quarter.
Overall updates
The non-oral care revenue growth focus is continued in all the regions and the business pipeline is ever strong to deliver the same. India revenue is expected to normalize with every passing quarter of this financial year. All other regions have delivered a strong revenue growth sequentially. Americas and Europe are expected to continue the growth trajectory. The lower margin in some of the geographies due to lower volumes/ product mix, initial expenditure incurred towards various strategic programmes and new location/ relocation like Assam and Russia in the H1 shall normalize going forward yielding benefits from these initiatives.
The revenue growth would have been higher but for India revenue growth, which is continued to be impacted by pharma regulation and lower offtake by key customer. India revenue is also impacted by transporter strike. Adjusted for the same the consolidated revenue growth would have been at 10.6% and 12.3% for the quarter and YTD respectively (at constant currency 6.4% and 7.1% respectively).
Adjusted for India Pharma Regulation and transporter strike impact, EBIDTA would have been at 19.1% as against reported 18.2% and EBIT would have been at 12.7% as against reported 11.7%. The margin is also impacted due to time lag in RM price pass thru and product mix.
|